Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
Related deals
SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
Learn moreDolmen Engineering has been acquired by NIRAS
The private shareholders of Dolmen Engineering have sold the company to NIRAS. The integration will enable the two companies to strengthen their positions within the European life science and food & beverage sectors and offer a fully integrated suite of services.
Learn moreInMedica has acquired J. Pauliuko šeimos klinika
InMedica, the largest Lithuanian network of medical clinics, has acquired J. Pauliuko šeimos klinika.
Learn more